KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.

Shannon N Westin, Kathleen Moore, Hye Sook Chon, Jessica Thomes Pepin, Erin A Salinas, David Starks, Paul A Disilvestro, Brian Slomovitz, Elen Vettus, Fernando Gálvez-Montosa, Kofi Agyemang-Prempeh, Flora Zagouri, Jae-Weon Kim, Qinglei Gao, Fernando Contreras Mejia, Andreia Cristina De Melo, Tadaaki Nishikawa, Matthew Kowgier, Sonia Iyer, Ying Wang, Els Van Nieuwenhuysen

Gynecol Oncol 206 54-64

PMID41690202
PMCID-
DOI10.1016/j.ygyno.2026.01.777
发表日期2026-02-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

OBJECTIVE: The phase 3 DUO-E trial demonstrated statistically significant progression-free survival (PFS) benefit with carboplatin/paclitaxel plus durvalumab followed by durvalumab with/without olaparib maintenance versus carboplatin/paclitaxel alone in advanced/recurrent endometrial cancer. We report exploratory analyses of key biomarkers and histology in the mismatch repair proficient (pMMR) subpopulation. METHODS: Patients were randomised 1:1:1 to carboplatin/paclitaxel (control arm), carboplatin/paclitaxel plus durvalumab followed by durvalumab (durvalumab arm) or carboplatin/paclitaxel plus durvalumab followed by durvalumab plus olaparib (durvalumab + olaparib arm). The presence of and relationship between selected biomarkers and histology, and PFS were investigated in the pMMR subpopulation. RESULTS: Biomarkers of interest (programmed death-ligand 1 [PD-L1] expression and mutations in BRCA1/BRCA2 genes, homologous recombination repair genes, DNA polymerase epsilon and tumour protein 53 [TP53m]) were evaluable in 486/575 patients in the pMMR subpopulation, with 84% (n = 407) positive for ≥ 1 biomarker; PD-L1 positive (67%) and TP53m (59%) were the most prevalent biomarkers. In the biomarker-known subpopulation, 52% and 27% of patients had tumours of endometrioid and serous histology, respectively. In exploratory analyses, PFS hazard ratios were improved versus control for both treatment arms across multiple biomarker and histology known subgroups, and favoured the durvalumab + olaparib arm in the majority of assessed biomarker/histological subgroups. CONCLUSIONS: The DUO-E pMMR subpopulation was highly heterogeneous with frequent overlap of biomarkers and histology. Consistent with the primary analysis, durvalumab plus olaparib improved the PFS benefit observed with durvalumab versus control across a range of biomarker and histological subgroups.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。